文献速递白血病

基于早期反应的治疗分层改善成人早期胸腺前体急性淋巴细胞白血病生存:成人急性淋巴细胞白血病研究组研究

Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study.
PubMed 文献 · J Clin Oncol · 2017-06-12

该研究对GRAALL-2003和-2005研究中213例成人T细胞急性淋巴细胞白血病(T-ALL)患者(含47例早期胸腺前体(ETP)-ALL)进行临床生物学、遗传学和生存分析。结果显示ETP-ALL组5年总生存率为59.6%(95%CI 44.2%至72.0%),非ETP-ALL组为66.5%(95%CI 58.7%至73.2%),差异无统计学意义(P=0.33);异基因干细胞移植在大部分ETP-ALL患者中显示出有益效应。作者认为基于反应的风险分层和治疗强化可消除成人ETP-ALL的不良预后。

要点

  • ETP-ALL组5年总生存率59.6%,非ETP-ALL组66.5%,差异无统计学意义(P=0.33)。
  • ETP-ALL早期骨髓化疗耐药率高(87%),但采用GRAALL方案后预后不劣于非ETP-ALL组。
  • 异基因干细胞移植在大部分ETP-ALL患者中显示出有益效应。

核心结论

  • 作者认为,基于反应的风险分层和治疗强化可消除成人ETP-ALL的不良预后。

研究设计与样本

  • 对GRAALL-2003和-2005研究中213例成人T-ALL患者(包括47例ETP-ALL)进行全面的临床生物学、遗传学和生存分析。

主要发现

  • 靶向二代测序显示,免疫表型定义的成人T-ALL基因型与儿童相似,细胞因子受体和RAS信号通路相关因子突变率高(62.2%),造血发育相关因子突变率为29.7%,组蛋白化学修饰相关因子突变率为48.6%。
  • 与儿童病例不同,DNA甲基化因子基因突变也常见(32.4%)。
  • 尽管ETP-ALL早期骨髓化疗耐药率高达87%,但采用GRAALL方案治疗的成人ETP-ALL总体预后不劣于非ETP-ALL组(5年总生存率:ETP组59.6%,95%CI 44.2%至72.0%;非ETP组66.5%,95%CI 58.7%至73.2%;P=0.33)。
  • 异基因干细胞移植在大部分ETP-ALL患者中显示出有益效应。

关键数值与推荐

  • 5年总生存率:ETP-ALL组59.6%(95%CI 44.2%至72.0%),非ETP-ALL组66.5%(95%CI 58.7%至73.2%),P=0.33。
  • 早期骨髓化疗耐药率:ETP-ALL组87%。
  • 突变频率:细胞因子受体和RAS信号通路相关因子62.2%,造血发育相关因子29.7%,组蛋白化学修饰相关因子48.6%,DNA甲基化因子基因32.4%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Early thymic precursor (ETP) acute lymphoblastic leukemia (ALL) is an immunophenotypically defined subgroup of T-cell ALL (T-ALL) associated with high rates of intrinsic treatment resistance. Studies in children have shown that the negative prognostic impact of chemotherapy resistance is abrogated by the implementation of early response-based intensification strategies. Comparable data in adults are lacking. Patients and Methods We performed comprehensive clinicobiologic, genetic, and survival analyses of a large cohort of 213 adult patients with T-ALL, including 47 patients with ETP-ALL, treated in the GRAALL (Group for Research on Adult Acute Lymphoblastic Leukemia) -2003 and -2005 studies. Results Targeted next-generation sequencing revealed that the genotype of immunophenotypically defined adult T-ALL is similar to the pediatric equivalent, with high rates of mutations in factors involved in cytokine receptor and RAS signaling (62.2%), hematopoietic development (29.7%), and chemical modification of histones (48.6%). In contrast to pediatric cases, mutations in DNA methylation factor genes were also common (32.4%). We found that despite expected high levels of early bone marrow chemotherapy resistance (87%), the overall prognosis for adults with ETP-ALL treated using the GRAALL protocols was not inferior to that of the non-ETP-ALL group (5-year overall survival: ETP, 59.6%; 95% CI, 44.2% to 72.0% v non-ETP, 66.5%; 95% CI, 58.7% to 73.2%; P = 0.33) and that allogeneic stem-cell transplantation had a beneficial effect in a large proportion of patients with ETP-ALL. Conclusion Our results suggest that the use of response-based risk stratification and therapy intensification abrogates the poor prognosis of adult ETP-ALL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bond J, Graux C, Lhermitte L, et al. Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study. J Clin Oncol. 2017. PMID: 28605290. doi:10.1200/JCO.2016.71.8585

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。